Αποτελέσματα Αναζήτησης
12 Σεπ 2023 · We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency.
- Overview of ADNI MRI - Jack - 2024 - Alzheimer's & Dementia - Wiley ...
In addition to informing the design of clinical trials, ADNI...
- Overview of ADNI MRI - Jack - 2024 - Alzheimer's & Dementia - Wiley ...
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD).
This figure is a newly adapted schematic depicted in two previous Alzheimer’s Disease Neuroimaging Initiative (ADNI) reviews [47,124] that updates the current understanding of the hypothetical time line for the onset and progression of Alzheimer’s disease (AD) neurodegeneration and cognitive impairments progressing from normal controls (NC ...
11 Σεπ 2024 · In addition to informing the design of clinical trials, ADNI data have been used extensively for observational research in normal brain aging and dementia to examine correlations between MRI, clinical, genetic, positron emission tomography (PET), and biofluid measures.
1 Ιουλ 2015 · The overarching objective for the Alzheimer's Disease Neuroimaging Initiative (ADNI) magnetic resonance imaging (MRI) core has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.
This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use.
26 Φεβ 2008 · Abstract. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease.